Venus Remedies jumps on winning legal battle against French firm for paracetamol patent

18 Jun 2021 Evaluate

Venus Remedies is currently trading at Rs. 329.85, up by 1.95 points or 0.59% from its previous closing of Rs. 327.90 on the BSE.

The scrip opened at Rs. 344.25 and has touched a high and low of Rs. 344.25 and Rs. 321.00 respectively. So far 35140 shares were traded on the counter.

The BSE group 'B' stock of face value Rs. 10 has touched a 52 week high of Rs. 352.55 on 23-Apr-2021 and a 52 week low of Rs. 50.50 on 19-Jun-2020.

Last one week high and low of the scrip stood at Rs. 344.25 and Rs. 309.35 respectively. The current market cap of the company is Rs. 443.65 crore.

The promoters holding in the company stood at 35.89%, while Institutions and Non-Institutions held 0.04% and 64.07% respectively.

Venus Remedies has won a 10-year-long patent battle against French firm SCR Pharmatop with regards to production of the intravenous paracetamol solution in the country. The Indian drug firm had initiated the legal battle in order to remove any patent hurdle in manufacturing of intravenous paracetamol solution in the country.

Venus Remedies is one of the handful player in pharmaceutical sector to launch world global injectable manufacturers. It has world-class manufacturing facilities in Panchkula and Baddi (in India) and Werne (in Germany) and research and development center in Venus Medicine Research Centre (in India).

Venus Remedies Share Price

769.00 -28.15 (-3.53%)
17-Dec-2025 16:01 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1791.95
Dr. Reddys Lab 1271.00
Cipla 1497.45
Zydus Lifesciences 917.85
Lupin 2109.70
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×